ADITXT INC
ADTXNASDAQ🏆 #5330 by market capEarnings Dec 2US Equity
——
Quote unavailableTrack ADTX
Get earnings, price moves & breaking news on Telegram
24h—
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$299,393
Small Cap
📈Revenue Growth (YoY)
-74.1%
Declining
📊Gross Margin
19.9%
Thin
💵FCF Margin
—
⚖️P/S Ratio
20.9x
Expensive
Otter Score
—
Insufficient data
No chart data available for ADTX.
Trading Snapshot
- Day Range
- —
- 52-Week Range
- $0.00 – $7,985.52
- Volume (shares)
- —
- Avg Volume (shares)
- —
- Shares Outstanding
- 998.0M
- Next Earnings
- 2026-12-02
Fundamentals Snapshot
- Annual Revenue
- $3,195
- Last Q Revenue
- $12,159
- P/E Ratio
- —
- P/S Ratio
- 20.9x
- EPS (TTM)
- $-205,055.95
- Dividend Yield
- —
- Dilution (1yr)
- −28.0%
ADITXT INC
ADTXFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$3K▼ −97.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
8.4%▼ −102.3% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$20M▼ −29.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$25.7B▲ +153234.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
37K▼ −28.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$192K▲ +$6M YoY
StockOtter · stockotter.spaceAbout ADITXT INC
Aditxt Inc. is an innovative biotechnology company dedicated to transforming healthcare through its proprietary immune modulation and personalized medicine platform. Focused on enhancing immune responses to address chronic diseases and allergies, Aditxt aims to significantly improve patient outcomes. With a robust pipeline of therapeutic candidates supported by comprehensive research and strategic collaborations, the company is poised to be a leader in the rapidly evolving field of immune-based therapies. Aditxt's commitment to scientific advancement and patient-centric solutions positions it at the forefront of immunology and the broader healthcare landscape.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.
Latest News & Updates
News unavailable.